What is NDC 25021-795?

25021-795 is the product NDC for levetiracetam, Levetiracetam 15 mg/mL injection, solution, listed with the FDA by Sagent Pharmaceuticals. It has 1 package NDC, shown above in 10- and 11-digit form.

Sagent Pharmaceuticals, NDC labeler code 25021. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for levetiracetam?

260 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

levetiracetam NDC 25021-795 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)25021-795Labeler and product segments. Claims need a package NDC.

Product NDC at billing width25021-0795Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
25021-795-82	2502107958225021079582	10 BAG in 1 CARTON (25021-795-82) / 100 mL in 1 BAGMarketed from Sep 15, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): levetiracetam
Generic name (nonproprietary): levetiracetam
Active ingredients: Levetiracetam — 15 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Sagent PharmaceuticalsNDC labeler code 25021
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206880
Marketing start: Sep 15, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 25021-795_15958c84-c55b-4873-8a99-ec32b7446900SPL ID 15958c84-c55b-4873-8a99-ec32b7446900SPL set ID d2de9565-0c0b-4957-bafa-1a286103709eRxCUI 1193358, 1193360, 1193362UNII 44YRR34555

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N425021079582 followed by a unit qualifier and the quantity

Package 25021-0795-82. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 18, 2024.

Indications (excerpt from the label)

Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults (≥16 years of age) with the following seizure types when oral administration is temporarily not feasible: Partial-onset seizures ( 1.1 ) Myoclonic seizures in patients with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures ( 1.3 ) 1.1 Partial-Onset Seizures Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of myoclonic seizur…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 25021-795

What is NDC 25021-795?: 25021-795 is the product NDC for levetiracetam, Levetiracetam 15 mg/mL injection, solution, listed with the FDA by Sagent Pharmaceuticals. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: levetiracetam.
What is the active ingredient?: Levetiracetam.
Who is the labeler?: Sagent Pharmaceuticals, NDC labeler code 25021. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for levetiracetam?: 260 other product NDCs are listed under this name. See all levetiracetam NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other levetiracetam NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Levetiracetam	Levetiracetam 500 mg/1	Tablet, Film coatedOral	Cardinal Health 107, LLC	55154-0288	55154-0288-00
Levetiracetam	Levetiracetam 750 mg/1	Tablet, Film coated, Extended releaseOral	REMEDYREPACK INC.	70518-4731	70518-4731-00
Levetiracetam	Levetiracetam 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Baxter Healthcare Corporation	36000-265	36000-0265-0536000-0265-10
Levetiracetam	Levetiracetam 1000 mg/1	TabletOral	Direct_Rx	72189-679	72189-0679-6072189-0679-82
Levetiracetam	Levetiracetam 500 mg/1	Tablet, Film coatedOral	Unit Dose Solutions, Inc.	87441-046	87441-0046-01
Levetiracetam	Levetiracetam 500 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-0420	67046-0420-03
Levetiracetam	Levetiracetam 500 mg/1	Tablet, Film coatedOral	Injecta Medcial LLC	87234-0035	87234-0035-01
Levetiracetam	Levetiracetam 1000 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-0863	67046-0863-03
Levetiracetam	Levetiracetam 500 mg/1	TabletOral	Coupler LLC	67046-2094	67046-2094-03
Levetiracetam	Levetiracetam 250 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-0880	67046-0880-03

All 261 levetiracetam NDCs

Other NDCs under ANDA 206880

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206880
Product	Strength	Form · route	Labeler	Product NDC
levetiracetam	Levetiracetam 5 mg/mL	Injection, SolutionIntravenous	Sagent Pharmaceuticals	25021-793
levetiracetam	Levetiracetam 10 mg/mL	Injection, SolutionIntravenous	Sagent Pharmaceuticals	25021-794
Levetiracetam	Levetiracetam 15 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-154
Levetiracetam	Levetiracetam 5 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-152
Levetiracetam	Levetiracetam 10 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-153
Levetiracetamlevetiracetam injection	Levetiracetam 5 mg/mL	InjectionIntravenous	Dr.Reddy's Laboratories Inc	43598-635
Levetiracetamlevetiracetam injection	Levetiracetam 10 mg/mL	InjectionIntravenous	Dr.Reddy's Laboratories Inc	43598-636
Levetiracetamlevetiracetam injection	Levetiracetam 15 mg/mL	InjectionIntravenous	Dr.Reddy's Laboratories Inc	43598-637
Levetiracetamlevetiracetam injection	Levetiracetam 5 mg/mL	InjectionIntravenous	Dr.Reddy's Laboratories Inc	43598-755
Levetiracetamlevetiracetam injection	Levetiracetam 10 mg/mL	InjectionIntravenous	Dr.Reddy's Laboratories Inc	43598-757
Levetiracetamlevetiracetam injection	Levetiracetam 15 mg/mL	InjectionIntravenous	Dr.Reddy's Laboratories Inc	43598-759